NEWS

Case Study Identifies New Trigger for CAR–T Cell Expansion in DLBCL in JCAR017 Trial
AJMC.com Managed Markets Network
Chimeric antigen receptor (CAR)-T cells can re-expand in a patient months after the initial infusion and can also be active against the patient’s cancer. These are the findings of a single case study that was recently published in the New England …

RegenxBio to Acquire Dimension Tx in Combo of Gene Therapy Companies
Xconomy
Dimension Therapeutics has agreed to be acquired by RegenxBio, the gene therapy developer that originally helped form the company four years ago. RegenxBio, based in Rockville, MD, will pay $3.41 per share in the all-stock deal. By comparison …
Regenxbio bags one of its gene therapy vector partners, buying out a struggling DimensionEndpoints News
Regenxbio to buy battered Dimension for gene therapiesFierceBiotech
Rockville biotech buys Cambridge gene therapy firm for $86MWashington Business Journal
Genetic Engineering & Biotechnology News –BioPharma Dive
all 21 news articles »

Five myths about gene editing
Washington Post
In February 2016, one CRISPR critic predicted in Mother Jones, “We are this close to ‘designer babies.’ ” And this month, biologist Richard Dawkins mused that the genetically edited “designer babies ” on the horizon shouldn’t be any more worrisome than …
CRISPR co-creator: We should have freedom to choose our ‘genetic destiny’Genetic Literacy Project

all 2 news articles »

Immunotherapy Triggers Release of Mitochondrial DNA and Trips Alarm
Genetic Engineering & Biotechnology News (press release)
Now, a group of researchers at UT Southwestern Medical Center report on their new finding that describe how cancer immunotherapy causes stressed tumor cells to release their mitochondrial DNA into nearby immune cells, triggering a host alert system.

Regenxbio to buy battered Dimension for gene therapies
FierceBiotech
Regenxbio has penned a deal to acquire Dimension Therapeutics. The takeover will see Regenxbio pay about $86 million to add two of early-stage gene therapies to its pipeline. Rockville, Maryland-based Regenxbio swooped on Dimension to gain the …
RegenxBio to Acquire Dimension Tx in Combo of Gene Therapy CompaniesXconomy
Regenxbio bags one of its gene therapy vector partners, buying out a struggling DimensionEndpoints News
Rockville biotech buys Cambridge gene therapy firm for $86MWashington Business Journal
Genetic Engineering & Biotechnology News –BioPharma Dive
all 23 news articles »

Regenxbio to buy battered Dimension for gene therapies
FierceBiotech
Regenxbio has penned a deal to acquire Dimension Therapeutics. The takeover will see Regenxbio pay about $86 million to add two of early-stage gene therapies to its pipeline. Rockville, Maryland-based Regenxbio swooped on Dimension to gain the …
RegenxBio to Acquire Dimension Tx in Combo of Gene Therapy CompaniesXconomy
Regenxbio bags one of its gene therapy vector partners, buying out a struggling DimensionEndpoints News
Rockville biotech buys Cambridge gene therapy firm for $86MWashington Business Journal
Genetic Engineering & Biotechnology News –BioPharma Dive
all 23 news articles »

Dosing underway in Sangamo’s early-stage study of gene therapy SB-525 in hemophilia A
Seeking Alpha
The first patient has been treated in a Phase 1/2 clinical trial, Alta, assessing Sangamo Therapeutics’ (NASDAQ:SGMO) gene therapy candidate SB-525. The open-label dose-ranging study will evaluate the safety and tolerability of SB-525 in 20 adults with …
Sangamo And Pfizer Announce First Patient Receives Treatment In Phase 1/2 Clinical Trial Evaluating SB-525 …Markets Insider

all 4 news articles »